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Reply to the Editor:
We are gratified by Dr Anderson’s solid
endorsement of our editorial, helping to
clarify this rather confused and confusing
situation surrounding the use of the word
“actual” in the assessment of intrinsic valve
performances. We fully agree with him re-
garding the importance of the concept of
competing risks environment. His propos-
als on reporting long-term experiences with
replacement heart valves are excellent, and
we recommend that future authors follow
his advice.
The letter by Grunkemeier, Takken-
berg, and Jamieson incorrectly summarizes
in its first paragraph the content of our
editorial and therefore adds unnecessary
confusion. Dr Bodnar was probably the
first to introduce competing risks to cardiac
surgery; Dr Blackstone and colleagues
have used competing risks analyses exten-
sively in multiple settings of adult and,
particularly, congenital heart disease, and
both will continue to do so to answer ques-
tions that methodology was designed to
answer. The method is not the problem!
The problem is its inappropriate use in an-
swering questions related to intrinsic prop-
erties of heart valve substitutes, such as
comparative durability. From its beginning,
our editorial was clear about the specific,
focused context of our remarks. Rather
than restate the entire editorial to make 1
point clear, perhaps an analogy would be
helpful.
Pretend we wish to compare durability
(tread life) of 3 brands of tire. (We under-
stand that, just like structural valve deteri-
oration [SVD], this is a continuous process
and not an event; for simplicity, however,
we will estimate durability by the time to
change tires because of excessive tread
wear, just as we may estimate SVD by time
to valve replacement.) Likely there are spe-
cific risk factors for tire durability, but let
us imagine that miles traveled is the stron-
gest (just as young age is the strongest
correlate of SVD). Now, let us say that our
study of tire durability for brand A is dom-
inated by a fleet of cars operated by trav-
eling salespersons, study of brand B by
commuters living within 5 miles of work,
and study of brand C by mothers with
children involved in many after-school ac-
tivities. After a stated period, most sales-
persons have had to change tires, a number
of mothers have, but few short-distance
commuters have. Should we conclude that
A and C tires wear out too fast, and we
should switch to brand B? If we instead
compare the tires in a distance-specific
fashion using time-to-event (actuarially
based) analysis methods, we would be get-
ting closer to a fair comparison of brands
A, B, and C by isolating tire properties
from the driving specifics of their owners.
In the case of SVD, the only universally
found risk factor is age of patient at im-
plant, so age-specific durability provides a
reasonable comparison of bioprosthetic de-
vice durability. As with the tires, estimates
of durability are properly made by time-to-
event-type analyses.
You may then ask: What tire should we
recommend for the driving habits of a
given person? The answer may well de-
pend on how long different people intend
to keep their cars. A person who leases a
new car every 3 years no matter how little
he or she drives may never need to change
tires. Trading in a car, like death of a pa-
tient, is a competing risk. For someone who
drives little, there is no reason to pay a
premium for a tire of superior durability if
at trade-in there is unlikely to be much
tread wear! However, it is important to
understand that the car-trading habits of
owners do not themselves affect intrinsic
properties of the tires. So, interesting as
competing risks analysis is for answering
some questions such as those posed, for
simply comparing intrinsic durability of
tires, these trading habits are extraneous
and should not be allowed to confound the
comparison.
Choice of a prosthesis for a given pa-
tient, like choice of a tire, may well depend
on a number of factors, such as the pa-
tient’s expected longevity, which itself has
many correlations that are unrelated to in-
trinsic properties of the device. These are
appropriately evaluated by competing risks
analyses. However, longevity of the per-
son, like car-trading habits, is a far more
complex matter than the intrinsic properties
of the prostheses. Estimates of whether or
not a patient will live to experience SVD of
their prosthesis will be different for every
patient, despite the prosthesis retaining its
unchanged intrinsic durability.
It is important to recognize that in both
time-to-event and competing risks meth-
ods, time to SVD and time to death are
assumed to be completely independent of
one another. Thus, the fundamental “actu-
arial” calculation for each component of a
competing risks analysis can be performed
independently of one another, after which a
mathematical combination is made. Thus,
actuarial estimates are fundamental and un-
changing, whereas competing risk esti-
mates will vary, depending on what set of
events is considered competing or ignored.
(You may protest that it is irrational to
think there is no linkage between SVD and
death, and you are probably right. How-
ever, that is the assumption that both “ac-
tuarial” and competing risks methods as-
sume. Methods for dealing with linked
events, called methods for “informative
censoring,” are still not well developed.)
In conclusion, we suggest that Drs
Grunkemeier, Takkenberg, Jamieson, and
Miller need to realize the magnitude of the
mistake they make. Actuarial analysis and
cumulative incidence assessment are not
competing but complementary methods.
One is apple, the other orange, and oranges
should not be blamed for not being apples.
The question is not which is better—the
question is which should be used for what
purpose. Cumulative incidence cannot be
used to assess let alone compare intrinsic
valve properties. We were not advocating
that articles employing competing risks
analysis appropriately be “banned” from
our journals but that research focused on
long-term intrinsic performance of replace-
ment heart valves and their comparison not
be published with inappropriate analyses of
competing risks.
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Reporting “actual freedom” should
not be banned
To the Editor:
The life of a bioprosthetic heart valve usu-
ally ends as a result of structural valve
deterioration (SVD) or death of the patient.
In this competing risks situation, the prob-
ability of SVD is estimated by the cumu-
lative incidence function, sometimes re-
ferred to as “actual” analysis.
The editorial by Bodnar and Blackstone
published in the January 2006 issue of the
Journal1 criticized this method and recom-
mended its prohibition. Specifically,
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